Kos Advicor "Approvable"; Firm Will Likely Target High-Risk Patients
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Patients with coronary heart disease, diabetes or "metabolic syndrome" represent particularly promising groups for initial therapy with Advicor, Kos Chairman and CEO Daniel Bell said during the company’s second quarter earnings conference call Aug. 1.